Targeting specific proteins in brain tumors to improve treatment outcomes
Targeting Neoantigens in Glioblastoma
This study is looking at how we can use the immune system to better fight glioblastoma, a serious brain cancer, by focusing on special proteins made by the tumor, and it invites patients with newly diagnosed glioblastoma to join a trial that combines personalized vaccines with treatments to boost their immune response.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Massachusetts General Hospital NIH-funded |
| Lab location | 1 site (Boston, United States) |
| Project ID | NIH-10456986 on NIH RePORTER |
What this research studies
This research investigates how the immune system can be harnessed to fight glioblastoma, a deadly brain cancer, by focusing on neoantigens—unique proteins produced by tumor cells. The study aims to understand how certain immune cells, known as dendritic cells, can effectively present these neoantigens to the immune system, thereby enhancing the body's response to the tumor. Patients with newly diagnosed glioblastoma may have the opportunity to participate in a clinical trial that combines personalized vaccines targeting these neoantigens with checkpoint blockade therapy, which helps to unleash the immune response against the tumor.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals who have been newly diagnosed with glioblastoma and are seeking innovative treatment options.
Not a fit: Patients with advanced glioblastoma or those who have already undergone extensive treatment may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective treatments for glioblastoma, potentially improving survival rates and quality of life for patients.
How similar studies have performed: Other research has shown promising results in targeting neoantigens in various cancers, indicating that this approach may be effective in glioblastoma as well.
Where this research is happening
Boston, United States
- Massachusetts General Hospital — Boston, United States (Active)
Researchers
- Principal investigator: Dunn, Gavin Peter — Massachusetts General Hospital
- Study coordinator: Dunn, Gavin Peter
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.